Rolapitant HCl (SCH619734; SCH-619734; SCH 619734; Varubi), the hydrochloride salt of Rolapitant, is a CNS penetreable and orally bioavailable antagonist of neurokinin (NK1) receptor (Ki = 0.66 nM) that was approved in 2015 to prevent delayed nausea and vomiting caused by cancer chemotherapy.

SB-222200 is a novel, potent, selective, reversible, brain penetrant and competitive antagonist of human NK-3 receptor with Ki of 4.4 nM.

Rolapitant (formerly SCH-619734; SCH619734; trade name: Varubi) is a selective, CNS penetrant and orally bioactive neurokinin (NK1) receptor antagonist (Ki = 0.66 nM) with antiemetic activity.

Vapreotide (trade name: Sanvar) is a synthetic somatostatin analog and a NK1R antagonist with an IC50 of 330 nM.

Maropitan (CJ11972; CJ11972) is a novel, potent, selective and orally bioactive antagonist of neurokinin (NK1) receptor.

Aprepitant (formerly known as MK-0869; MK-869; L-754030; trade name: Emend) is a novel, selective and high-affinity small molecule antagonist of neurokinin 1 receptor with a Kd of 86 pM.

AZD2624 (also known as AZD-4901, MLE-4901, AZ-12472520, and AZD-2624) is a novel, potent, selective and orally bioactive neurokinin-3 receptor (NK3R) antagonist.

Fosaprepitant (also known as L-758298; MK0517) is a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.

Netupitant (formerly CID-6451149; AGE-94200; Ro 67-3189) is an orally bioavailable neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity.

Eprazinone diHCl, the dihydrochloride salt of Eprazinone, is a novel and potent neurokinin 1 receptor (NK1R) ligand with mucolytic, secretolytic, and bronchial antispasmodic activities.